9 yr. study of anti-Ro52 & ILD pts -- 1,026 pts 15% Ro52+: interstitial pneumonia w/ autoimmune 48%, CTD-ILD 13%, idiopathic pulm fibrosis 10%, hypersens pneumonitis 6%, idiopathic ILD 24%. Ro52+ were younger w/ more autoimmune dz, +MSA Abs, ILD progression, death, & lung https://t.co/fuFfnaYIRd

Flow cytometry on Peripheral blood can help patient stratification in RA A cluster rich in TEMRA Terminally Differentiated Effector Memory T Cells is associated with response to treatment and therapeutic decision taking into account showed higher remission 39% vs. 24% Next https://t.co/8ZZ2epf7LK

• https://x.com/AurelieRheumo/status/1964220962075005190/photo/1

In #scleroderma pts with cardiac involvement, the presence of ventricular ectopy is assocd w/ ⬆️risk of mortality & SCD. ☝️these arrythmias present late so consider it in pts w/established dse who develop new-onset cardiac symptoms @RheumNow #APLAR25 @rheumarhyme @marklagacmd https://t.co/MTDfxevqwb

• https://x.com/RHEUMarampa/status/1964217545202016537/photo/1

2025 Update of EULAR RA management recommandation Summary slide inspired from Josef Smolen’s presentation @RheumNow #APLAR25 https://t.co/wRzeX9OIry https://t.co/djrd7O9G9H

• https://x.com/AurelieRheumo/status/1964218576426139723/photo/1
• https://twitter.com/aurelierheumo/status/1963765001400758305

Is it #lupus? Interesting study by @escheriKYA et al. showing comparable diagnostic performance of SLERPI (93%) in 🇵🇭 patients vs. SLICC and EULAR/ACR criteria A practical alternative tool that can be used by clinicians in a resource-limited setting 🤔 @RheumNow #APLAR25 https://t.co/xByBkjEr3r

• https://x.com/RHEUMarampa/status/1964197781163085839/photo/1
• https://x.com/RHEUMarampa/status/1964197781163085839/photo/1

Key takeaways of trabecular bone screening: 📌Complements but doesnt replace BMD/FRAX in fracture risk assessment 📌Dont exclude any lumbar spine unless w/significant change like laminectomy 📌Can use in monitoring untreated pts since TBS declines @RheumNow #APLAR25 https://t.co/bcN83IDDja

• https://x.com/RHEUMarampa/status/1964182142780346407/photo/1

Remember! ☝️ Trabecular bone screening should not be routinely used in pre-menopausal women. @RheumNow #APLAR25 #osteoporosis https://t.co/hGMExyDYUX

• https://x.com/RHEUMarampa/status/1964177254503895271/photo/1

Cross-sectional study of 320 dermatomyositis (198 classic DM, 122 amyopathic DM/CADM) & compared myositis panels for ANA, MSA, MAA, etc. Comparing CDM vs CADM - ANA pos in 63% vs 49%, p<0.05; MSA+ 47% vs 40% (NS); MAA+ 29% vs 26%(NS); MSA&MAA neg 40% vs 48% (NS)

Japanese retrospective real world study shows antifibrotic use assoc w/ better survival in Pulm Fibrosis-ILD for 1st 3 yrs & improved survival in progressive pulm. fibrosis (PPF) “despite management” (PPF subset prev Rx non-antifibrotic therapy) https://t.co/caiIuhg7j8 https://t.co/N0ST73TMoR

• https://buff.ly/4nhpTUS

3 yr study of FDA Adverse Event Reporting on anifrolumab shows following AEs- URIs, herpes zoster, infusion reactions, and potential new risks like dyspnea and pyrexia, not in the label. https://t.co/vP2YWGT2vR https://t.co/BruGBtXEBu

• Post-marketing safety signals of anifrolumab in systemic lupus erythematosus: a…

Sjogren's Disease Interstitial Lung Disease Dr. Nancy Carteron, a rheumatologist in northern California, discusses interstitial lung disease in Sjogren's disease, as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month of September 2025. https://t.co/lA1vrBiar4